Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/sumitomo-pharma-oncology-to-present-preliminary-clinical-data-evaluating-investigational-agent-tp-3654-at-the-64th-ash-annual-meeting--exposition-301667810.html
https://www.prnewswire.com/news-releases/sumitomo-pharma-oncology-receives-orphan-drug-designation-for-dsp-0390-an-investigational-emopamil-binding-protein-ebp-inhibitor-for-the-treatment-of-brain-cancer-301587648.html
https://www.prnewswire.com/news-releases/sumitomo-pharma-oncology-presents-new-data-from-investigational-pipeline-of-novel-cancer-therapeutics-at-aacr-annual-meeting-2022-301521150.html
https://www.prnewswire.com/news-releases/sumitomo-dainippon-pharma-oncology-provides-update-on-phase-3-wizard-201g-study-of-ombipepimut-s-emulsion-dsp-7888-in-patients-with-recurrent-or-progressive-glioblastoma-301444814.html
https://www.prnewswire.com/news-releases/sumitomo-dainippon-pharma-oncology-announces-first-patient-dosed-in-phase-1-dose-expansion-study-of-tp-1287-in-patients-with-sarcoma-301414798.html
https://www.prnewswire.com/news-releases/sumitomo-dainippon-pharma-oncology-announces-phase-3-canstem303c-study-of-napabucasin-fails-to-reach-primary-endpoints-in-patients-with-previously-treated-metastatic-colorectal-cancer-301224902.html
https://www.prnewswire.com/news-releases/sumitomo-dainippon-pharma-oncology-announces-first-patient-dosed-in-phase-12-study-of-tp-0184-for-the-treatment-of-anemia-in-patients-with-low-or-intermediate-risk-myelodysplastic-syndromes-301209572.html
https://www.prnewswire.com/news-releases/sumitomo-dainippon-pharma-oncology-announces-first-patient-dosed-in-phase-12-study-of-tp-0184-for-the-treatment-of-anemia-in-patients-with-low-or-intermediate-risk-myelodysplastic-syndromes-301209572.html
https://endpts.com/lynn-seely-hits-the-exit-as-myovant-graduates-to-commercial-space-handing-the-reins-to-amgen-vet/
https://www.prnewswire.com/news-releases/sumitomo-dainippon-pharma-oncology-presents-findings-from-phase-2-zella-201-clinical-study-evaluating-investigational-agent-alvocidib-in-patients-with-acute-myeloid-leukemia-at-62nd-ash-annual-meeting-301186807.html